Condition: Primary Membranous Nephropathy · Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
This description comes directly from the study's public registry record.
Zhe Zhang · +0518-81220121 · zhe.zhang@hengrui.com
Always discuss trial participation with your own doctor first.
| General hospital of eastern theater command | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07289763